The high-priority National Security Space Launch Phase 3 missions include six launches in FY2027, nine in FY2028 and 10 in ...

A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33 (IL-33), an alarmin cytokine. This targeted approach is expected to reduce airway inflammation and ...

Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient ...

Mossad signals Phase 3 strategy to destabilise Iran from within as blockade risks economic collapse, rising unrest and ...

Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of alternative endpoints in phase 3 oncology trials ...

Theialife, a late-stage clinical company advancing innovative therapeutic solutions for ocular diseases, today announced the appointment of Thomas Ruggia as President and Chief Executive Officer. Mr.